A detailed history of Nuveen Asset Management, LLC transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 447,092 shares of TBPH stock, worth $4.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
447,092
Previous 342,715 30.46%
Holding current value
$4.41 Million
Previous $2.91 Million 23.98%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.66 - $10.25 $799,527 - $1.07 Million
104,377 Added 30.46%
447,092 $3.6 Million
Q2 2024

Aug 09, 2024

BUY
$8.29 - $9.92 $1.52 Million - $1.81 Million
182,897 Added 114.44%
342,715 $2.91 Million
Q4 2023

Feb 14, 2024

SELL
$8.58 - $11.4 $40,926 - $54,378
-4,770 Reduced 2.9%
159,818 $1.8 Million
Q3 2023

Nov 14, 2023

BUY
$8.38 - $10.44 $60,830 - $75,783
7,259 Added 4.61%
164,588 $1.42 Million
Q2 2023

Aug 14, 2023

BUY
$10.16 - $11.92 $28,641 - $33,602
2,819 Added 1.82%
157,329 $1.63 Million
Q1 2023

May 15, 2023

SELL
$9.87 - $11.44 $962,690 - $1.12 Million
-97,537 Reduced 38.7%
154,510 $1.68 Million
Q4 2022

Feb 14, 2023

BUY
$9.65 - $11.34 $732,184 - $860,411
75,874 Added 43.07%
252,047 $2.83 Million
Q3 2022

Nov 14, 2022

SELL
$8.39 - $10.22 $536,867 - $653,967
-63,989 Reduced 26.64%
176,173 $1.79 Million
Q2 2022

Aug 15, 2022

BUY
$8.41 - $10.34 $447,882 - $550,667
53,256 Added 28.49%
240,162 $2.18 Million
Q1 2022

May 16, 2022

BUY
$8.33 - $12.96 $184,226 - $286,623
22,116 Added 13.42%
186,906 $1.81 Million
Q4 2021

Feb 14, 2022

SELL
$7.42 - $11.05 $88,498 - $131,793
-11,927 Reduced 6.75%
164,790 $1.65 Million
Q3 2021

Nov 12, 2021

SELL
$6.77 - $14.41 $74,165 - $157,861
-10,955 Reduced 5.84%
176,717 $1.26 Million
Q2 2021

Aug 16, 2021

SELL
$14.52 - $22.46 $61,201 - $94,668
-4,215 Reduced 2.2%
187,672 $2.73 Million
Q1 2021

May 17, 2021

BUY
$16.57 - $21.08 $28,616 - $36,405
1,727 Added 0.91%
191,887 $3.92 Million
Q4 2020

Feb 16, 2021

SELL
$14.89 - $20.16 $289,952 - $392,575
-19,473 Reduced 9.29%
190,160 $3.38 Million
Q3 2020

Nov 16, 2020

SELL
$14.79 - $22.49 $89,035 - $135,389
-6,020 Reduced 2.79%
209,633 $3.1 Million
Q2 2020

Aug 14, 2020

SELL
$20.64 - $30.69 $1.79 Million - $2.65 Million
-86,492 Reduced 28.63%
215,653 $4.53 Million
Q1 2020

May 14, 2020

BUY
$17.84 - $31.21 $538,660 - $942,354
30,194 Added 11.1%
302,145 $6.98 Million
Q4 2019

Feb 14, 2020

SELL
$16.12 - $25.89 $94,140 - $151,197
-5,840 Reduced 2.1%
271,951 $7.04 Million
Q3 2019

Nov 14, 2019

BUY
$16.51 - $23.78 $936,100 - $1.35 Million
56,699 Added 25.64%
277,791 $5.41 Million
Q2 2019

Aug 15, 2019

BUY
$15.6 - $25.15 $3.45 Million - $5.56 Million
221,092 New
221,092 $3.61 Million

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $658M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.